PCRX Pacira Biosciences Inc.

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.

One employee received stock options to purchase an aggregate of 3,500 shares of Pacira common stock and seven employees received restricted stock units for an aggregate of 12,300 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of $23.21 per share, the closing trading price of Pacira common stock on the Nasdaq Global Select Market on the date of grant. Each restricted stock unit represents the contingent right to receive one share of Pacira common stock and the restricted stock unit awards vest annually in four equal installments beginning on July 1, 2026.

Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit



Investor Contact:
Susan Mesco, (973) 451-4030
 

Media Contact:
Sara Marino, (973) 370-5430
 
EN
03/07/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacira Biosciences Inc.

 PRESS RELEASE

Pacira to Report Second Quarter 2025 Financial Results on Tuesday Augu...

Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answ...

 PRESS RELEASE

Pacira BioSciences Announces Strategic Collaboration to Significantly ...

Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market reach of ZILRETTA® (triamcinolone acetonide extended-...

 PRESS RELEASE

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule...

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), th...

 PRESS RELEASE

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’...

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025 - Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark & Leah’s Story Highlights the Impact of Non-Opioid Solutions - BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the debut of a powerful new spotlighting the journey of a couple who, after navigating t...

 PRESS RELEASE

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single...

Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee -- PCRX-201 demonstrated sustained clinical efficacy with improvements in pain, stiffness, and function for up to three years – BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new long-term follow-up data from its Phase ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch